Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements

Miller M., Tokgozoglu L., Parhofer K. G., Handelsman Y., Leiter L. A., Landmesser U., ...Daha Fazla

EXPERT REVIEW OF CARDIOVASCULAR THERAPY, cilt.20, sa.8, ss.609-625, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Sayı: 8
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/14779072.2022.2103541
  • Dergi Adı: EXPERT REVIEW OF CARDIOVASCULAR THERAPY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Chemical Abstracts Core, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.609-625
  • Anahtar Kelimeler: Atherosclerotic cardiovascular disease, icosapent ethyl, REDUCE-IT, guidelines, hypertriglyceridemia, PURIFIED EICOSAPENTAENOIC ACID, CORONARY-HEART-DISEASE, TRIGLYCERIDE-RICH LIPOPROTEINS, PRIMARY-PREVENTION, STATIN THERAPY, FATTY-ACIDS, FISH-OIL, HYPERCHOLESTEROLEMIC PATIENTS, CLINICAL ENDOCRINOLOGISTS, SECONDARY PREVENTION
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Introduction: REDUCE-IT demonstrated that adding 4 g/day of icosapent ethyl (IPE; purified ethyl ester of eicosapentaenoic acid [EPA]) to statins substantially reduced cardiovascular disease (CVD) events, with few adverse effects. These data prompted numerous leading medical societies across five continents, including the American College of Cardiology, the European Society of Cardiology, and the Japanese Circulation Society, to update their guidelines or scientific/consensus statements to recommend use of IPE for primary and secondary prevention of CVD events.